Advances in studies of tyrosine kinase inhibitors and their acquired resistance
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Advances in studies of tyrosine kinase inhibitors and their acquired resistance
Authors
Keywords
Cancer, Protein tyrosine kinase, Tyrosine kinase inhibitors, Acquired resistance
Journal
Molecular Cancer
Volume 17, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-02-15
DOI
10.1186/s12943-018-0801-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non–Small Cell Lung Cancer
- (2017) Satomi Watanabe et al. MOLECULAR CANCER THERAPEUTICS
- Osimertinib: A Review in T790M-Positive Advanced Non-Small Cell Lung Cancer
- (2017) Yvette N. Lamb et al. Targeted Oncology
- Resistance to epithelial growth factor receptor tyrosine kinase inhibitors in a patient with transformation from lung adenocarcinoma to small cell lung cancer: A case report
- (2017) Liying Fang et al. Oncology Letters
- Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
- (2017) Kirstine Jacobsen et al. Nature Communications
- Domain-dependent effects of insulin and IGF-1 receptors on signalling and gene expression
- (2017) Weikang Cai et al. Nature Communications
- Insulin-like growth factor-binding protein-3 inhibits IGF-1-induced proliferation of human hepatocellular carcinoma cells by controlling bFGF and PDGF autocrine/paracrine loops
- (2016) Yang Ma et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Sunitinib Possible Sex-Divergent Therapeutic Outcomes
- (2016) Ignacio Segarra et al. CLINICAL DRUG INVESTIGATION
- Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
- (2016) Shuhang Wang et al. Journal of Hematology & Oncology
- Cigarette smoke extract exposure induces EGFR-TKI resistance in EGFR-mutated NSCLC via mediating Src activation and EMT
- (2016) Dandan Li et al. LUNG CANCER
- Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis
- (2016) Yuan Wang et al. Drug Design Development and Therapy
- Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma
- (2016) Carl Koschmann et al. Oncotarget
- Prospective Validation of Rapid Plasma Genotyping for the Detection ofEGFRandKRASMutations in Advanced Lung Cancer
- (2016) Adrian G. Sacher et al. JAMA Oncology
- IGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias
- (2016) Samuel Gusscott et al. PLoS One
- Bosutinib for the treatment of chronic myeloid leukemia
- (2015) V. Doan et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Overexpression of EGFR Protein in Bruneian Lung Cancer Patients
- (2015) Yu Hao Han et al. Asian Pacific Journal of Cancer Prevention
- EGFR over-expression in non-small cell lung cancers harboring EGFR mutations is associated with marked down-regulation of CD82
- (2015) Chi-Hwa Yang et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Expanding the structural diversity of Bcr-Abl inhibitors: Hybrid molecules based on GNF-2 and Imatinib
- (2015) Xiaoyan Pan et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma
- (2015) Nadeera De Silva et al. BRITISH JOURNAL OF CANCER
- Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma
- (2015) E. A. Kuczynski et al. CANCER RESEARCH
- Mechanisms of lapatinib resistance in HER2-driven breast cancer
- (2015) Valentina D’Amato et al. CANCER TREATMENT REVIEWS
- Inhibition of crosstalk between Bcr-Abl and PKC signaling by PEITC, augments imatinib sensitivity in chronic myelogenous leukemia cells
- (2015) Madhumita Roy et al. CHEMICO-BIOLOGICAL INTERACTIONS
- EGFR T790M resistance mutation in non small-cell lung carcinoma
- (2015) Marc G. Denis et al. CLINICA CHIMICA ACTA
- InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma
- (2015) Y. Ma et al. CLINICAL CANCER RESEARCH
- Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non-Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR
- (2015) M. Watanabe et al. CLINICAL CANCER RESEARCH
- Ceritinib (LDK378): A Potent Alternative to Crizotinib for ALK-Rearranged Non–Small-Cell Lung Cancer
- (2015) Sen Li et al. Clinical Lung Cancer
- Inhibition of the VEGF/VEGFR Pathway Improves Survival in Advanced Kidney Cancer: A Systematic Review and Meta-Analysis
- (2015) Roberto Iacovelli et al. CURRENT DRUG TARGETS
- Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?
- (2015) I. Watermann et al. Diagnostic Pathology
- Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma
- (2015) Naoshi Nishida et al. DIGESTIVE DISEASES
- Anti-tumor activity of sorafenib in a model of a pediatric hepatocellular carcinoma
- (2015) Carmen Nagel et al. EXPERIMENTAL CELL RESEARCH
- A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients
- (2015) Alana Dikopf et al. Expert Opinion On Drug Safety
- Analogs, formulations and derivatives of imatinib: a patent review
- (2015) Francesca Musumeci et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Tivantinib (ARQ197) in hepatocellular carcinoma
- (2015) Camillo Porta et al. Expert Review of Anticancer Therapy
- The role of BRAF in the pathogenesis of thyroid carcinoma
- (2015) Hui-Xiong Xu Frontiers in Bioscience-Landmark
- Refining sorafenib therapy: lessons from clinical practice
- (2015) Luigi Bolondi et al. Future Oncology
- Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulateVEGFR2in breast cancer cells
- (2015) Neil T. Pfister et al. GENES & DEVELOPMENT
- Epigenetic-based therapy: From single- to multi-target approaches
- (2015) Rosaria Benedetti et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Curcumin potentiates the anti-leukemia effects of imatinib by downregulation of the AKT/mTOR pathway and BCR/ABL gene expression in Ph+ acute lymphoblastic leukemia
- (2015) Yong Guo et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Protein-tyrosine Phosphatase and Kinase Specificity in Regulation of SRC and Breast Tumor Kinase
- (2015) Gaofeng Fan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The prognostic impact of EGFR, ErbB2 and MET gene amplification in human gastric carcinomas as measured by quantitative Real-Time PCR
- (2015) Ghasem Janbabai et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer
- (2015) Tu Nguyen-Ngoc et al. Journal of Thoracic Oncology
- The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma
- (2015) Sally K. Martin et al. LEUKEMIA RESEARCH
- Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR -mutated lung cancer via an EGFR signal
- (2015) Yosuke Togashi et al. LUNG CANCER
- Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus
- (2015) Federico Cappuzzo et al. LUNG CANCER
- Neoadjuvant Dual HER2-Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER2-Positive Breast Cancer: A Meta-Analysis of Randomized Prospective Clinical Trials
- (2015) M. Hicks et al. ONCOLOGIST
- Gefitinib and Erlotinib in Metastatic Non-Small Cell Lung Cancer: A Meta-Analysis of Toxicity and Efficacy of Randomized Clinical Trials
- (2015) M. Burotto et al. ONCOLOGIST
- Targeting Epidermal Growth Factor Receptor–Related Signaling Pathways in Pancreatic Cancer
- (2015) Philip A. Philip et al. PANCREAS
- MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells
- (2015) Dario Presutti et al. PLoS One
- The EML4-ALK oncogene: targeting an essential growth driver in human cancer
- (2015) Hiroyuki MANO PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES
- Discovering the first tyrosine kinase
- (2015) Tony Hunter PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Effects of Pazopanib, Sunitinib, and Sorafenib, Anti-VEGF Agents, on the Growth of Experimental Endometriosis in Rats
- (2015) Caglar Yildiz et al. Reproductive Sciences
- Gefitinib: a review of its use in adults with advanced non-small cell lung cancer
- (2015) Sohita Dhillon Targeted Oncology
- Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma
- (2015) Hannah A. Blair et al. Targeted Oncology
- VEGFR1 and VEGFR2 in lip carcinogenesis and its association with microvessel density
- (2015) Carla Ariotti et al. TUMOR BIOLOGY
- A dynamically coupled allosteric network underlies binding cooperativity in Src kinase
- (2015) Zachariah H. Foda et al. Nature Communications
- Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis
- (2015) Guangchao Cao et al. MEDICAL SCIENCE MONITOR
- Mechanisms of resistance to EGFR tyrosine kinase inhibitors
- (2015) Lihua Huang et al. Acta Pharmaceutica Sinica B
- Targeting RTK Signaling Pathways in Cancer
- (2015) Tarik Regad Cancers
- PTEN: Multiple Functions in Human Malignant Tumors
- (2015) Michele Milella et al. Frontiers in Oncology
- Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
- (2015) Gregory M. Botting et al. PLoS One
- MET amplification as a potential therapeutic target in gastric cancer
- (2015) Hisato Kawakami et al. Oncotarget
- Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice
- (2015) Sandra Dupouy et al. Oncotarget
- Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention
- (2015) Nicole M. Davis et al. Oncotarget
- CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells
- (2015) Jianfeng Han et al. Scientific Reports
- Suppression of Dicer Increases Sensitivity to Gefitinib in Human Lung Cancer Cells
- (2014) Jui-Chieh Chen et al. ANNALS OF SURGICAL ONCOLOGY
- Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer
- (2014) H J Lee et al. BRITISH JOURNAL OF CANCER
- Gene Signature-Guided Dasatinib Therapy in Metastatic Breast Cancer
- (2014) L. Pusztai et al. CLINICAL CANCER RESEARCH
- Non-receptor protein tyrosine kinases signaling pathways in normal and cancer cells
- (2014) Elzbieta Gocek et al. CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
- Ceritinib: First Global Approval
- (2014) Sohita Dhillon et al. DRUGS
- EGFR inhibitor Gefitinib attenuates posterior capsule opacification in vitro and in the ex vivo human capsular bag model
- (2014) Christian Wertheimer et al. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
- Transcriptional and epigenetic control of IGF1R gene expression: Implications in metabolism and cancer
- (2014) Haim Werner et al. GROWTH HORMONE & IGF RESEARCH
- Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients
- (2014) J.L. Kuiper et al. LUNG CANCER
- High EGFR gene copy number predicts poor outcome in triple-negative breast cancer
- (2014) Heae Surng Park et al. MODERN PATHOLOGY
- The Capable ABL: What Is Its Biological Function?
- (2014) J. Y. J. Wang MOLECULAR AND CELLULAR BIOLOGY
- Clinical Targeting of Mutated and Wild-Type Protein Tyrosine Kinases in Cancer
- (2014) J. M. Drake et al. MOLECULAR AND CELLULAR BIOLOGY
- Acquired resistance to TKIs in solid tumours: learning from lung cancer
- (2014) D. Ross Camidge et al. Nature Reviews Clinical Oncology
- Alteration in Mir-21/PTEN Expression Modulates Gefitinib Resistance in Non-Small Cell Lung Cancer
- (2014) Hua Shen et al. PLoS One
- Functional differentiation of cytotoxic cancer drugs and targeted cancer therapeutics
- (2014) Gian C. Winkler et al. REGULATORY TOXICOLOGY AND PHARMACOLOGY
- The soluble VEGFR1 concentration in the serum of patients with colorectal cancer
- (2014) Oranus Abbasi et al. SURGERY TODAY
- MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
- (2014) Ibrahim C. Haznedaroglu Mediterranean Journal of Hematology and Infectious Diseases
- Imatinib and Beyond in Gastrointestinal Stromal Tumors: A Radiologist's Perspective
- (2013) Sree Harsha Tirumani et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- The midkine family of growth factors: diverse roles in nervous system formation and maintenance
- (2013) C Winkler et al. BRITISH JOURNAL OF PHARMACOLOGY
- Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor
- (2013) Akito Hata et al. CANCER
- VEGFR, RET, and RAF/MEK/ERK Pathway Take Part in the Inhibition of Osteosarcoma MG63 Cells with Sorafenib Treatment
- (2013) Jiong Mei et al. CELL BIOCHEMISTRY AND BIOPHYSICS
- Cell survival and metastasis regulation by Akt signaling in colorectal cancer
- (2013) Ekta Agarwal et al. CELLULAR SIGNALLING
- Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration-Effect Data to Support Clinical Development
- (2013) H. Xiang et al. CLINICAL CANCER RESEARCH
- Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET--Response
- (2013) P. Michieli et al. CLINICAL CANCER RESEARCH
- Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET
- (2013) C. Basilico et al. CLINICAL CANCER RESEARCH
- IGF2 and cancer
- (2013) Callum Livingstone ENDOCRINE-RELATED CANCER
- Erlotinib in the first-line treatment of non-small-cell lung cancer
- (2013) Manolo D’Arcangelo et al. Expert Review of Anticancer Therapy
- Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
- (2013) Ann-Lii Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: A systematic review and meta-analysis of clinical trials
- (2013) Liang Shi et al. LUNG CANCER
- Receptor Tyrosine Kinase (RTK) Signalling in the Control of Neural Stem and Progenitor Cell (NSPC) Development
- (2013) Alexander Annenkov MOLECULAR NEUROBIOLOGY
- Overview and Management of Cardiac Adverse Events Associated With Tyrosine Kinase Inhibitors
- (2013) D. J. Lenihan et al. ONCOLOGIST
- Lapatinib alters the malignant phenotype of osteosarcoma cells via downregulation of the activity of the HER2-PI3K/AKT-FASN axis in vitro
- (2013) XIN-HUA LONG et al. ONCOLOGY REPORTS
- Combination of EGFR-TKIs and Chemotherapy as First-Line Therapy for Advanced NSCLC: A Meta-Analysis
- (2013) Pu-Yun OuYang et al. PLoS One
- Multifarious functions of PDGFs and PDGFRs in tumor growth and metastasis
- (2013) Yihai Cao TRENDS IN MOLECULAR MEDICINE
- VEGFR and Type-V RTK Activation and Signaling
- (2013) M. Shibuya Cold Spring Harbor Perspectives in Biology
- Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells
- (2013) J Chen et al. Cell Death & Disease
- The Capicua repressor - a general sensor of RTK signaling in development and disease
- (2012) G. Jimenez et al. JOURNAL OF CELL SCIENCE
- The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor
- (2012) Y. Kim et al. MOLECULAR CANCER THERAPEUTICS
- Structural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase Domain
- (2012) Nicholas M. Levinson et al. PLoS One
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- EGFR T790M Mutation: A Double Role in Lung Cancer Cell Survival?
- (2010) Kenichi Suda et al. Journal of Thoracic Oncology
- Enhanced Anticancer Effect of the Combination of BIBW2992 and Thymidylate Synthase-Targeted Agents in Non-Small Cell Lung Cancer with the T790M Mutation of Epidermal Growth Factor Receptor
- (2010) K. Takezawa et al. MOLECULAR CANCER THERAPEUTICS
- The role of signaling pathways in the development and treatment of hepatocellular carcinoma
- (2010) S Whittaker et al. ONCOGENE
- Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions
- (2009) Hester van Cruijsen Frontiers in Bioscience-Landmark
- Human aortic smooth muscle cells are insulin resistant at the receptor level but sensitive to IGF1 and IGF2
- (2009) S I Chisalita et al. JOURNAL OF MOLECULAR ENDOCRINOLOGY
- Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4
- (2009) Todd D Prickett et al. NATURE GENETICS
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- (2008) D Li et al. ONCOGENE
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
- (2008) C.-H. Yun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now